Navigation Links
Surprising Cystic Fibrosis Finding That Could Be A Helpful Treatment Option

Cystic fibrosis is a genetic disease where the patient has frequent respiratory infections, breathing difficulties and eventually permanent lung damage. // It’s believed that patients with CF have too much mucus in their airways. But new research shows patients actually have too little mucus.

Researchers say that may studies have been done in the past , but it has never proven, that CF causes the body to produce too much abnormally thick mucus that accumulates in the lungs and intestines . However recent studies have shown that these patients actually have very little mucus in their airways.

For the study, researchers collected sputum from 12 patients with CF and 11 patients without lung disease. Sputum is the mucus that is coughed up when someone has a deep cough. After analyzing the sputum, researchers found the CF patients had less than the healthy participants. Researchers say the substance that clogs the lungs of CF patients is actually pus. They suspect the airways in CF patients are chronically infected and fill up with pus. They think that by adding mucus, it could reduce the infection and the amount of pus.

Specialists say that if further studies prove that mucus is protective against the bacteria, they might have a new treatment option for CF which would make a wonderful difference in quality of life of the patient.
'"/>




Page: 1

Related medicine news :

1. Blood Pressure Levels Across The Globe Show Surprising Drop
2. Surprising Interaction Between Genes, Gender, and Hypertension
3. Tamoxifen Discontinuation Rates Surprisingly High
4. Increases in Autism Rates Not Surprising to Education Expert
5. Gene Therapy For Cystic Fibrosis
6. The Use Of Colistin To Treat Cystic Fibrosis Questioned
7. Cystic fibrosis patients may require a new treatment for bacterial infection
8. Treatment for Cystic Fibrosis in the future
9. New Therapy Discovered By Scientists For Cystic Fibrosis
10. Inhaling Concentrated Saline Could Benefit Cystic Fibrosis Patients
11. New Multi-functional Sensing Tool To Investigate Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: